MannKind (NNFN) AI Stock Analysis

10 Followers

MannKind

(Frankfurt:NNFN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Revenue Growth and Gross MarginMannKind has demonstrated substantial commercial expansion, with revenue rising sharply over several years and gross margin remaining high. This combination indicates improving product traction and attractive unit economics, giving the company a stronger base to fund launches, development programs, and future growth.

Negative Factors

Negative Equity and Elevated DebtNegative equity and elevated debt leave MannKind with limited balance-sheet cushion if operating results weaken. This stressed capital structure increases dependence on continued commercial execution and external financing, while interest and funding needs can constrain investment flexibility over the next several quarters.

MannKind (NNFN) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.17B
Dividend Yield: ―
Average Volume (3M): 2,530
Price to Earnings (P/E): -26.7
Beta (1Y): 0.73
Revenue Growth: 21.56%
EPS Growth: -214.11%
Country: Germany
Employees: 592
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

MannKind Business Overview & Revenue Model

Company Description

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within t...

MannKind Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:-8.79%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

The call was strongly optimistic, with management reporting delivery of all three 2026 catalysts, 43% year-over-year quarterly revenue growth, strong early Afrezza pediatric adoption, FUROSCIX growth, ReadyFlow approval, and positive nintedanib safety results. The main negatives were the quarterly net loss, significantly higher operating expenses, Afrezza adult softness and payer friction, FUROSCIX affordability and second-half execution requirements, the ReadyFlow supply-chain delay, and continued regulatory uncertainty for nintedanib. The number and significance of the stated achievements outweighed the challenges.

Positive Updates

All Three 2026 Strategic Catalysts Delivered

MannKind stated that it delivered on all three catalysts identified for 2026: Afrezza pediatric approval, FUROSCIX ReadyFlow approval, and positive Phase 1b results for nintedanib DPI in patients with IPF.

Negative Updates

Quarterly Net Loss Replaced Prior-Year Net Income

MannKind reported a GAAP net loss of $19 million in Q2 2026, compared with GAAP net income of $700,000 in the prior-year quarter. Non-GAAP net loss was $2.7 million, compared with non-GAAP net income of $13.9 million in Q2 2025.

Company Guidance

Management expects FUROSCIX revenue of $110 million-$120 million for 2026, with inventory shifting between the auto-injector and on-body infuser in Q3 and Q4; manufacturing-related revenues are expected to be in line with the prior year, with Q2 the highest quarter. FUROSCIX ReadyFlow will be available by the end of this month, with inventory expected by the end of the week of August 10th or the following Monday, and FUROSCIX margin is expected to increase by about 70% with the transition from OBI to ReadyFlow, with a large majority of 2027 expected to be ReadyFlow. Afrezza’s 2-unit cartridge is expected hopefully in 2027, high concentration formulations are expected as we approach 2028, and work on high doses will take another 12-18 months. The nintedanib DPI Phase 2 study is expected to continue activating sites throughout 2026, with FDA feedback expected in the fall; the working assumption is at least one trial for IPF and likely additional data generated in other target populations.

MannKind Risk Analysis

MannKind disclosed 51 risk factors in its most recent earnings report. MannKind reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

MannKind Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:NNFN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INVA	75Outperform	$1.52B	4.30	30.03%	―	18.17%	693.83%
XERS	69Neutral	$1.85B	-106.59	-426.33%	―	36.33%	54.68%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LXRX	46Neutral	$640.74M	-9.71	-40.40%	―	-29.03%	54.11%
SVRA	41Neutral	$971.83M	-8.19	-90.28%	―	―	-12.40%

* Healthcare Sector Average

Performance Comparison

DE:NNFN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:NNFN	MannKind Corporation	3.10	-1.82	-36.98%
LXRX	Lexicon Pharmaceuticals	1.46	0.08	5.80%
INVA	Innoviva	20.93	2.70	14.81%
SVRA	Savara	4.75	0.72	17.87%
XERS	Xeris Pharmaceuticals	10.35	0.48	4.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

MannKind AI Stock Analysis